Solid tumors

- Strengthening of T cell research expertise to develop next-generation T cell therapies for patients with limited or no treatment options ROTTERDAM, January 17, 2023 - Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated…

TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research completed a qualitative study titled "Solid Tumors Market" with 100+ market data tables, pie charts, graphs, and figures spread across Pages and an easy-to-grasp full…

SANTA ANA, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell therapies, today announced that the…

SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors,…

MONMOUTH JUNCTION, N. J. , May 06, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that Geno Germano, CEO and President of Elucida…

The mutations investigated in this study, however, are also found in other cancers, which extends the possible applications of these findings. "This is the first study to discover that the altered…

-  Study to evaluate the safety and tolerability of XRD-0394 in combination with palliative radiation therapy -  Major milestone for the company with first asset reaching clinical development DURHAM, N.C., Aug. 25, 2021 (GLOBE…

London, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Glycosylation Analysis Services Market, 2021 – 2030” report to its list of offerings. Profiling and in-depth characterization of glycosylated…

Los Angeles, USA, May 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Kinase Inhibitor Pipeline Analysis: Key Pharma Companies, and Emerging Therapies Offering New Horizons in Cancer Care Several pharmaceutical companies are developing the…